drugset / Trial / NCT03358277

Aripiprazole Added on for DMDD in Youths With ADHD

NCT03358277

NaSingle-groupOpen-labelTreatment

Summary

Objectives: 1. To investigate the effectiveness of adjuvant with aripiprazole to methylphenidate for disruptive mood dysregulation disorder (DMDD) in youths with attention-deficit/hyperactivity disorder (ADHD) 2. To investigate the neural basis of chronic irritability in youths with functional magnetic resonance imaging (fMRI) 3. To compare the clinical characteristics of youths with comorbid ADHD and DMDD to youths with ADHD only

Timeline

Start
2014-11-19
Primary completion
2017-08-12
Completion
2017-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 2.5 mg
Subject Aripiprazole Other / unclassified 5 mg
Subject Methylphenidate Small molecule 10 mg
Subject Methylphenidate Small molecule 18 mg
Subject Methylphenidate Small molecule 36 mg
Subject Methylphenidate Small molecule 40 mg